Fulcrum Therapeutics, Inc.’s Revenue Growth at a glance
Fulcrum Therapeutics, Inc. reports revenue growth of 2,752% for Dec 2024. The prior period recorded -55.8% (Dec 2023). Year over year the metric moved +2,807.8 pts (+5,034.5%). The rolling three-period average stands at 876.5%. Data last refreshed Dec 7, 2025, 2:49 AM.
Latest reading
2,752% · Dec 2024
YoY movement
+2,807.8 pts (+5,034.5%)
Rolling average
876.5%
Current Revenue Growth
2,752%
+2,807.8 pts
+5,034.5%
Rolling average
876.5%
Latest Value
2,752%
Dec 2024
YoY Change
+2,807.8 pts
Absolute
YoY Change %
+5,034.5%
Rate of change
3-Period Avg
876.5%
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s revenue growth stands at 2,752% for Dec 2024. Year-over-year, the metric shifted by +2,807.8 pts, translating into a +5,034.5% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How revenue growth shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports revenue growth of 2,752%. Evaluate revenue acceleration, seasonality, and long-term expansion for U.S. equities using annual growth data.
How to read revenue growth
Consistent double-digit revenue growth typically indicates demand strength and market share gains. Sharp decelerations may point to competitive or macro headwinds.
Balancing growth with profitability
Growth only creates value when paired with improving margins or cash generation. Pair revenue growth with profitability metrics to judge overall health.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s revenue growth profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current revenue growth?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports revenue growth of 2,752%. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s revenue growth trending year over year?
Year-over-year, the figure shifts by +2,807.8 pts (+5,034.5%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does revenue growth matter for Fulcrum Therapeutics, Inc.?
Revenue growth measures the percentage change in top-line sales compared with the prior period. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s revenue growth above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at 876.5%. Comparing the latest reading of 2,752% to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s revenue growth refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:49 AM and updates automatically every 24 hours, keeping your valuation inputs current.